Harrow, Inc. (HROW): Operating Income
$30.52M
Year ended 2025-12-31
-$2.75M
Trailing 12 months to 2026-06-30
+151.5%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.52M | +245.9% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $8.82M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $431.0K | -77.5% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $1.92M | +18.9% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $1.61M | +319.2% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $385.0K | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$4.79M | n/m | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | -$5.22M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$12.16M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$15.88M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$14.82M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$10.15M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$7.69M | n/m | 2015-03-12, From 2013-01-01 |
| 2012-12-31 | -$4.18M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$939.2K | n/m | 2013-03-18, From 2011-01-01 |
| 2010-12-31 | -$2.50M | n/a | 2012-02-23, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $30.52M | +245.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | -$1.05M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $41.00M | n/m |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$118.50M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$166.90M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $24.90M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $98.50M | +5.8% |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$32.66M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$386.00M | n/m |
Compare HROW, VREOF, LGND, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗